Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER Positive, HER2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Not applicableActive Not RecruitingNCT03503799
What this trial is testing

Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer

Who this might be right for
Primary Invasive Breast CancerEstrogen Receptor Positive TumorHuman Epidermal Growth Factor Receptor 2 Negative Tumor
North Eastern German Society of Gynaecological Oncology 1,191
Large-scale testing (Phase 3)Looking for participantsNCT06195709
What this trial is testing

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Who this might be right for
Breast Carcinoma
Institut Curie 300
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Testing effectiveness (Phase 2)WithdrawnNCT04901299
What this trial is testing

Fulvestrant + Neratinib In Breast Cancer

Who this might be right for
Stage IV (Metastatic) Breast CancerMetastatic Breast CancerER Positive Breast Cancer+3 more
Massachusetts General Hospital
Early research (Phase 1)Active Not RecruitingNCT03616587
What this trial is testing

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 396
Large-scale testing (Phase 3)UnknownNCT05985187
What this trial is testing

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Who this might be right for
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 412
Testing effectiveness (Phase 2)Study completedNCT02049957
What this trial is testing

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Calithera Biosciences, Inc 118
Large-scale testing (Phase 3)WithdrawnNCT03658213
What this trial is testing

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

Who this might be right for
Breast Cancer
AstraZeneca
Not applicableActive Not RecruitingNCT04118192
What this trial is testing

NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer

Who this might be right for
Breast Cancer
University of Birmingham 72
Testing effectiveness (Phase 2)Ended earlyNCT00674557
What this trial is testing

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

Who this might be right for
Breast Cancer
Cancer Research UK 111
Not applicableUnknownNCT02875951
What this trial is testing

Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer

Who this might be right for
ER Positive, HER2 Negative Breast Cancer Neoplasms
KU Leuven 100
Testing effectiveness (Phase 2)Looking for participantsNCT06259929
What this trial is testing

NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
Fondazione Oncotech 51
Not applicableWithdrawnNCT03080428
What this trial is testing

Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer

Who this might be right for
ER-positive Her2-negative Early Breast Cancer
UNICANCER
Testing effectiveness (Phase 2)Study completedNCT03628066
What this trial is testing

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Who this might be right for
Breast Cancer
NSABP Foundation Inc 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT06247995
What this trial is testing

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 20
Large-scale testing (Phase 3)Active Not RecruitingNCT02488967
What this trial is testing

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Who this might be right for
Breast AdenocarcinomaEstrogen Receptor NegativeHER2/Neu Negative+7 more
NRG Oncology 782